JAMES HENSEL: Open Payments
NPI 1023757937 · MONTGOMERY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,387 in 105 payments from 14 companies in 2025. Trend: 2023 $102 · 2024 $480 · 2025 $2,387
Food & beverage: $2,387
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 16 | $442 |
| Vanda Pharmaceuticals Inc. | 12 | $315 |
| Neurocrine BioSciences, Inc. | 13 | $291 |
| Janssen Pharmaceuticals, Inc | 8 | $278 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $220 |
| ABBVIE INC. | 16 | $208 |
| Otsuka America Pharmaceutical, Inc. | 8 | $179 |
| Corium, LLC | 8 | $171 |
| E.R. Squibb & Sons, L.L.C. | 4 | $86 |
| Tris Pharma Inc | 5 | $85 |
Products named: FANAPT, ARISTADA, INGREZZA, CAPLYTA, VRAYLAR, Azstarys, SPRAVATO, LYBALVI.
Industry payments across AL — which companies pay providers there.
